BOSTON--(BUSINESS WIRE)-- GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward “Tad” Stewart, who joins the team as Chief Business Officer (CBO).

Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years. He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch. Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics. Prior to his role at Ribon he served as President and CEO of Commense, Inc., Chief Business Officer of Crescendo Biologics, and spent many years with Merrimack Pharmaceuticals in various roles, including SVP of Business Development and Head of Commercial. Mr. Stewart received his MBA from Cornell University.

“We are thrilled to have Tad join our executive team. His deep experience in business development and transactions will be instrumental to our partnering activities, and his expertise in product development will accelerate our commercialization efforts,” said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. “Tad is an established leader in biotechnology, and his unique combination of transactional and strategic savvy will be a great asset to GRObio as we continue to advance our platform and pipeline.”

About GRO Biosciences

GRO Biosciences (“GRObio”) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Company’s NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by George Church, PhD of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005427/en/